Breast Cancer Female Clinical Trial
Official title:
A Randomized, Double-blind, Parallel Study Comparing Efficacy and Safety of Pegcyte (Nanogen) and Reference Product Neulastim (Roche) for Prevention of Chemotherapy (Accelerated AC Regimen)Induced Neutropenia in Breast-cancer Patients.
Verified date | December 2017 |
Source | Nanogen Pharmaceutical Biotechnology Joint Stock Company |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Accelerated AC regimen-Doxorubicin 60 mg/m2,Cyclophosphamide 600 mg/m2 on day 1 & day 14 of each cycle along with G-CSF support for up to 4 cycles, followed by Paclitaxel 175 mg/m2 in the next 4 cycles is the standard clinical practice in Vietnam for breast cancer, this regimen is to facilitate the dose-dense schedule, patients receive every-2-week therapy along with G-CSF support. the accelerated dose-dense schedule improve disease-free and overall survival among women with breast cancer .Primary objective of this study is to compare the efficacy and safety of Nanogen's Pegcyte and Roche's Neulastim for prevention of chemotherapy (Accelerated AC regimen)-induced neutropenia on breast cancer patients. Breast cancer patients scheduled to receive myelosuppressive chemotherapy (AC regimen) will be recruited in this trial. All eligible patients receive single subcutaneous injection of study drugs 24 hours after chemotherapy administration in each cycle for 3 consecutive cycles. Efficacy and safety assessments will be assessed based on the incidence of severe neutropenia in combination of temperature > 38.3℃ or sepsis or life threatening infection and incidence of serious adverse events.
Status | Completed |
Enrollment | 128 |
Est. completion date | November 6, 2017 |
Est. primary completion date | November 6, 2017 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Female patients aged between 18 - 65 years. - Patients with histological confirmed primary invasive breast cancer; stage I, II or III. - Patients had no prior chemotherapy treatments. - Patients scheduled to undergo myelosuppressive Doxorubicin and Cyclophosphamide chemotherapy for 04 cycles, and Paclitaxel chemotherapy for the next 04 cycles; patients were available for 14 days of each cycle for the first 03 chemotherapy cycles. - Patients with baseline ANC = 1.5 x 109/L, PLT = 100 x 109/L, HgB = 9 g/dL, WBC = 3,000/mL and albumin = 3.0 g/dL. - Performance status as per ECOG (Eastern Cooperative Oncology Group) score 0, 1 or 2. - Willing to give written and signed informed consent. Exclusion Criteria: - Patients with prior exposure of G-CSF or GM-CSF or its pegylated products in clinical development less than 6 months prior to randomization. - Myelotoxic concomitant treatment such as chloramphenicol, methotrexate, immunomodulating agents, interferons during 10 days before randomization. - Received systemic antibiotic treatment within 72 hours of chemotherapy. - Chronic use of corticosteroids, prior bone marrow or stem cell transplant. - Patients who had an immediate/ concurrent exposure to radiotherapy or surgery (within 4 weeks). - Severe medical disease: cardiovascular, hepatic, renal, pulmonary… - Known cases of hematological disease (sickle cell anemia, AML…) - History of HIV positive, active hepatitis. - Pregnant and lactating women or patients planning to become pregnant. - Known allergic reactions to study medications. - Positive to anti-pegfilgrastim antibody test |
Country | Name | City | State |
---|---|---|---|
Vietnam | Vietnam National Cancer Institute (Hospital K) | Hanoi |
Lead Sponsor | Collaborator |
---|---|
Nanogen Pharmaceutical Biotechnology Joint Stock Company |
Vietnam,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of patients who developed Febrile neutropenia in cycle 1,2 and 3 | 0 to 42 days) | ||
Secondary | Incidence of grade 4 severe neutropenia | in cycle 1,2 and 3 (0 to 14 , 28 and 42 days) | ||
Secondary | Incidence of antibiotics use | in cycle 1,2 and 3 (0 to 14 , 28 and 42 days) | ||
Secondary | Incidence of adverse events | in cycle 1,2 and 3 (0 to 14 , 28 and 42 days) | ||
Secondary | Changes in laboratory safety parameters | including vital signs | in cycle 1,2 and 3 (0 to 14 , 28 and 42 days) | |
Secondary | Presence of antibodies against Pegfilgrastim | at the end of cycle 3 (42 day) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03080623 -
Ultrasound-based Diagnostic Model for Differentiating Malignant Breast Lesion From Benign Lesion
|
||
Completed |
NCT05527769 -
Pain and Functional Recovery After Mastectomy and IBR by Implant: Prepectoral Versus Subpectoral Technique
|
||
Completed |
NCT06376578 -
Exercise Interventions for Improving Health in Breast Cancer Survivors
|
N/A | |
Completed |
NCT03004534 -
A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide
|
Early Phase 1 | |
Recruiting |
NCT05020574 -
Microbiome and Association With Implant Infections
|
Phase 2 | |
Active, not recruiting |
NCT06277141 -
The Vitality Mammography Messaging Study
|
N/A | |
Completed |
NCT03270111 -
High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women
|
N/A | |
Completed |
NCT03555227 -
USG PECS vs LIA for Breast Cancer Surgery
|
N/A | |
Active, not recruiting |
NCT03917082 -
Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05561842 -
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
|
||
Completed |
NCT04554056 -
Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06351332 -
A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined With Carboplatin and Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer (ZAP-IT)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03127995 -
Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence
|
N/A | |
Active, not recruiting |
NCT02237469 -
Prone Breast Radiotherapy Treatment Planning Observational Study
|
||
Completed |
NCT01204125 -
Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients
|
Phase 2 | |
Recruiting |
NCT04565054 -
Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC
|
Phase 3 | |
Recruiting |
NCT03956641 -
Evolution of the Physical Condition in Treated Cancer Patients
|
N/A | |
Recruiting |
NCT06087120 -
Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.
|
||
Recruiting |
NCT06058936 -
Exercises Using Virtual Reality on Cancer Patients
|
N/A | |
Completed |
NCT03470935 -
Non-interventional Study Evaluating Gynecological Impact of Diagnosis and Treatment of Breast Cancer in Patients Younger
|